BOCH
RARE icon

Blue Owl Capital Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Blue Owl Capital Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Sell
182,638
-120,000
-40% -$2.98M 0.92% 20
2026
Q1 		$6.34M Buy
302,638
+90,000
+42% +$2.03M 1.7% 14
2025
Q4 		$4.89M Sell
212,638
-209,800
-50% -$6.9M 1.51% 21
2025
Q3 		$12.7M Buy
422,438
+167,200
+66% +$5.01M 3.94% 9
2025
Q2 		$9.28M Buy
255,238
+102,000
+67% +$3.68M 3% 10
2025
Q1 		$5.55M Buy
153,238
+35,000
+30% +$1.46M 1.79% 15
2024
Q4 		$4.97M Sell
118,238
-45,000
-28% -$2.23M 1.15% 20
2024
Q3 		$9.07M Sell
163,238
-105,000
-39% -$5.35M 1.75% 15
2024
Q2 		$11M Hold
268,238
– – 3.07% 11
2024
Q1 		$12.5M Buy
268,238
+5,000
+2% +$236K 2.5% 12
2023
Q4 		$12.6M Buy
+263,238
New +$10.2M 3.01% 11

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Blue Owl Capital Holdings's RARE Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Ultragenyx Pharmaceutical (RARE) stake by 40% in Q2 2026, selling an estimated $2.98M and leaving 182,638 shares worth $6.1M. The position accounts for 0.92% of the portfolio, ranked #20.

Blue Owl Capital Holdings first reported a position in RARE in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.7M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Blue Owl Capital Holdings held 182,638 shares of Ultragenyx Pharmaceutical worth $6.1M as of Q2 2026.
  • Blue Owl Capital Holdings sold 120,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.98M.
  • Ultragenyx Pharmaceutical made up 0.92% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #20 holding.
  • Blue Owl Capital Holdings first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's Ultragenyx Pharmaceutical position peaked at $12.7M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.